Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
Apple shares fall amid WWDC conference 📉 No AI breakthrough?
The World Cup on the Market: Is There an Opportunity for Profit?
Intel gains 10% after talks with Google and Nvidia
US Open: Nasdaq rebounds as oil price falls 📈 Intel and Corning shares surge